RIGL
Rigel Pharmaceuticals Inc
46.60$
+1.7%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 820.6% | 217.4% | 311.3% | 1,031.9% | 0.6% | 1.5% | 0.8% | 0.7% | 1.5% | 6.1% | 10.4% | 6.7% | |
| -720.6% | -117.4% | -211.3% | -931.9% | 99.4% | 98.5% | 99.2% | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% | |
| 820.6% | 217.4% | 311.3% | 1,031.9% | 105.4% | 89.2% | 55.3% | 43.7% | 50.1% | 21.0% | 13.0% | 11.3% | |
| 385.5% | 61.6% | 102.6% | 843.7% | 157.3% | 125.8% | 70.5% | 61.6% | 93.5% | 95.0% | 63.1% | 39.4% | |
| 1,206.0% | 279.1% | 442.2% | 1,875.6% | 262.7% | 215.0% | 125.8% | 107.6% | 144.7% | 111.4% | 76.1% | 50.7% | |
| -1,106.0% | -179.1% | -342.2% | -1,775.6% | -163.3% | -116.5% | -26.7% | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 1.2% | 3.3% | 3.1% | 5.9% | 4.4% | 2.5% | |
| -1,101.9% | -178.1% | -339.6% | -1,739.3% | -158.3% | -112.8% | -27.4% | -11.6% | -48.7% | -21.5% | 10.2% | 41.4% | |
| -32.7% | -5.9% | 21.1% | -46.6% | 4.9% | -0.6% | 0.6% | 0.4% | 2.5% | 1.9% | 0.5% | -83.3% | |
| -1,101.9% | -178.1% | -339.6% | -1,739.3% | -158.3% | -112.2% | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% | |
| -1,077.5% | -174.1% | -309.2% | -1,729.0% | -162.0% | -111.1% | -25.5% | -7.6% | -44.8% | -14.5% | 15.9% | 44.7% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.